High
--
Open
--
VWAP
--
Vol
--
Mkt Cap
--
Low
--
Amount
--
EV/EBITDA(TTM)
--
Total Shares
--
EV
--
EV/OCF(TTM)
--
P/S(TTM)
--
Market Estimates
Earnings Estimates
Revenue
YoY Chg
EPS
YoYChg
FY2025Q2
FY2025Q3
FY2025Q4
662.50K
+13150%
-0.697
+10.67%
662.50K
+21983.33%
-0.944
+19.51%
1.16M
+116150%
-0.882
-2.01%
Estimates Revision
The market is revising No Change the revenue expectations for 4D Molecular Therapeutics, Inc. (FDMT) for FY2025, with the revenue forecasts being adjusted by 0% over the past three months. During the same period, the stock price has changed by 53.92%.
Revenue Estimates for FY2025
No Change
0.00%
In Past 3 Month
EPS Estimates for FY2025
No Change
0.00%
In Past 3 Month
Stock Price
Go Up
+53.92%
In Past 3 Month
6 Analyst Rating
Wall Street analysts forecast FDMT stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for FDMT is 29.40 USD with a low forecast of 17.00 USD and a high forecast of 38.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
5 Buy
0 Hold
1 Sell
Moderate Buy
Current: 11.190
Low
17.00
Averages
29.40
High
38.00
Current: 11.190
Low
17.00
Averages
29.40
High
38.00
RBC Capital
Lisa Walter
Outperform
maintain
$26 -> $32
2025-11-11
Reason
RBC Capital
Lisa Walter
Price Target
$26 -> $32
2025-11-11
maintain
Outperform
Reason
RBC Capital analyst Lisa Walter raised the firm's price target on 4D Molecular to $32 from $26 and keeps an Outperform rating on the shares after its Q3 results. The company's current cash position of $372M plus additional funds from the recent APAC deal with Otsuka and capital raise should extend the runway by 6 months into the second half of FY28 and fund both wAMD and DME pivotals, the analyst tells investors in a research note, adding that the recent funding "adds some cushion to the runway".
Barclays
Gena Wang
Overweight
downgrade
$38 -> $33
2025-11-11
Reason
Barclays
Gena Wang
Price Target
$38 -> $33
2025-11-11
downgrade
Overweight
Reason
Barclays analyst Gena Wang lowered the firm's price target on 4D Molecular to $33 from $38 and keeps an Overweight rating on the shares. The firm views the company's Q3 update as "largely incremental." The Otsuka deal and equity offering extend 4D's cash runway to the second half of 2028, the analyst tells investors in a research note.
Morgan Stanley
Judah Frommer
Underweight -> Equal Weight
upgrade
2025-11-06
Reason
Morgan Stanley
Judah Frommer
Price Target
2025-11-06
upgrade
Underweight -> Equal Weight
Reason
Morgan Stanley analyst Judah Frommer upgraded 4D Molecular to Equal Weight from Underweight. The firm is also raising its price target view on the stock to a range of $7-$16 from the prior range of $3-$7. Morgan Stanley notes that class safety concerns among physicians and commercial dynamics have driven its view of retinal disease gene therapy to date. The firm notes however that its new rating is based on the continued positive data for 4D-150, recent biopharma interest, and growing enthusiasm for 4D-150 among key opinion leaders, the analyst tells investors in a research note.
Leerink
Outperform
to
NULL
downgrade
$17 -> $16
2025-08-11
Reason
Leerink
Price Target
$17 -> $16
2025-08-11
downgrade
Outperform
to
NULL
Reason
Leerink lowered the firm's price target on 4D Molecular to $16 from $17 and keeps an Outperform rating on the shares after the company announced Q2 results and completion of enrollment in the lower dose cohorts of the Phase 1 trial of 4D-710 in cystic fibrosis. The firm's revised target reflects updated R&D expense estimates for ongoing pivotal trials, the analyst noted.
Barclays
Gena Wang
Overweight
downgrade
$45 -> $38
2025-05-09
Reason
Barclays
Gena Wang
Price Target
$45 -> $38
2025-05-09
downgrade
Overweight
Reason
Barclays analyst Gena Wang lowered the firm's price target on 4D Molecular to $38 from $45 and keeps an Overweight rating on the shares. The firm updated the company's model post the Q1 report.
B of A Securities
Tazeen Ahmad
Strong Buy
Maintains
$42 → $40
2025-03-10
Reason
B of A Securities
Tazeen Ahmad
Price Target
$42 → $40
2025-03-10
Maintains
Strong Buy
Reason
See All Ratings
Valuation Metrics
The current forward P/E ratio for 4D Molecular Therapeutics Inc (FDMT.O) is -1.36, compared to its 5-year average forward P/E of -5.95. For a more detailed relative valuation and DCF analysis to assess 4D Molecular Therapeutics Inc 's fair value, click here.
Forward PE
The forward P/E ratio is a valuation metric that divides a company's current stock price by its estimated future earnings per share over the next 12 months.
N/A
5Y Average PE
-5.95
Current PE
-1.36
Overvalued PE
-2.23
Undervalued PE
-9.67
Forward EV/EBITDA
The forward EV/EBITDA ratio is a valuation metric that divides a company's enterprise value (EV) by its estimated future earnings before interest, taxes, depreciation, and amortization (EBITDA) over the next 12 months.
N/A
5Y Average EV/EBITDA
-3.49
Current EV/EBITDA
0.94
Overvalued EV/EBITDA
0.95
Undervalued EV/EBITDA
-7.92
Forward PS
The forward P/S ratio is a valuation metric that divides a company's current stock price by its estimated future sales (or revenue) per share over the next 12 months.
N/A
5Y Average PS
129.64
Current PS
55.54
Overvalued PS
272.38
Undervalued PS
-13.09
Financials
Annual
Quarterly
N/A
Total Revenue
N/A
Operating Profit
N/A
Net Income after Tax
N/A
EPS - Diluted
N/A
Free Cash Flow
N/A
Gross Profit Margin - %
N/A
FCF Margin - %
N/A
Net Margin - %
Trading Trends
Insider
Insiders are Neutral. There are no significant trading trends over the last month.
Sold
Bought
Hedge Fund
Hedge Funds are Neutral. There are no significant trading trends over the last quarter.
Sold
Bought
Congress Trading
Congress are Neutral. There are no significant trading trends over the last month.
Sold
Bought
Insider
Insiders are Neutral. There are no significant trading trends over the last month.
Sold
Bought
FDMT News & Events
Events Timeline
(ET)
2025-11-17
06:08:56
Kristian Humer Appointed CFO of 4D Molecular
2025-11-10 (ET)
2025-11-10
08:05:06
4D Molecular anticipates funding to last through the second half of 2028.
2025-11-10
08:04:25
4D Molecular Announces Q3 Earnings Per Share of $1.01, Exceeding Consensus Estimate of 98 Cents
Sign Up For More Events
Sign Up For More Events
News
![[object Object]](https://d5bp8bijhhba2.cloudfront.net/image/default_image/newsfilter.png)
Preview
5.0
11-21NewsfilterNovaBridge's Visara Division Names Renowned Ophthalmology Experts as Chief Medical Officer and Chair of Scientific Advisory Board to Advance VIS-101
![[object Object]](https://d5bp8bijhhba2.cloudfront.net/image/cover_image/832ac0299f01185c40e5bf49a55daaf89b64e8e86dff28a48441ccde8557562d.png)
Preview
5.0
11-20GlobenewswireNovaBridge's Visara Division Names Renowned Ophthalmology Experts as Chief Medical Officer and Chair of Scientific Advisory Board to Advance VIS-101
![[object Object]](https://d5bp8bijhhba2.cloudfront.net/image/cover_image/5195b7ca07150771645c483a3c3f05b36c09ec1d3a4106ef46ede384485809b5.png)
Preview
5.0
11-17Yahoo Finance4D Molecular Therapeutics Appoints Kristian Humer as Chief Financial Officer
Sign Up For More News
People Also Watch
FAQ
What is 4D Molecular Therapeutics Inc (FDMT) stock price today?
What is 4D Molecular Therapeutics Inc (FDMT)'s business?
What is the price predicton of FDMT Stock?
What is 4D Molecular Therapeutics Inc (FDMT)'s revenue for the last quarter?
What is 4D Molecular Therapeutics Inc (FDMT)'s earnings per share (EPS) for the last quarter?
What changes have occurred in the market's expectations for 4D Molecular Therapeutics Inc (FDMT)'s fundamentals?
How many employees does 4D Molecular Therapeutics Inc (FDMT). have?